Metformin inhibits the growth of nasopharyngeal carcinoma cells and sensitizes the cells to radiation via inhibition of the DNA damage repair pathway. 2014

Haiwen Li, and Xinggui Chen, and Ying Yu, and Zhennan Wang, and Yufang Zuo, and Shuhui Li, and Donghong Yang, and Shengwen Hu, and Mei Xiang, and Zumin Xu, and Zhonghua Yu
Cancer Center, Affiliated Hospital of Guangdong Medical College, Zhanjiang, Guangdong 524000, P.R. China.

Nasopharyngeal carcinoma (NPC) is a leading cause of cancer-related mortality. Radiotherapy is one of the primary modalities for NPC treatment. However, in patients in the late stages of the disease, the local control rate and overall survival rate remain low. Therefore, it is urgent to identify new targets that can improve the outcome of radiotherapy in this neoplasm. In the present study, we investigated the effects of metformin on the radiosensitivity of NPC cells and explored the potential mechanisms. The radiosensitizing effects of metformin on NPC cells were measured by colony formation assay. Cell apoptosis was assessed by Hoechst 33342 staining analysis. DNA damage was detected by monitoring γ-H2AX foci with immunofluorescence. The changes in apotosis-related and DNA damage repair-related proteins were detected by western blotting. Our study demonstrated that metformin significantly reduced the cell viability, enhanced radiosensitivity and potentiated radiation-induced caspase-9/-3 cleavage in the NPC cells. In addition, metformin plus radiation significantly upregulated the expression of p-ATM, p-ATR, γ-H2AX and downregulated the expression of ATM, ATR, p95/NBS1, Rad50, DNA-PK, Ku70 and Ku80. Therefore, our results suggest that metformin possesses a strong radiosensitizing potential in NPC cells. This radiosensitizing effect was associated with inhibition of DNA double-strand break repair processes through HR repair and the NHEJ repair signaling pathway, thereby enhancing radiation-induced cell apoptosis. These findings imply that metformin is a potent radiation-sensitizing agent and may be a promising candidate for clinical evaluation as part of a combined regimen for the treatment of nasopharyngeal carcinoma.

UI MeSH Term Description Entries
D008687 Metformin A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289) Dimethylguanylguanidine,Dimethylbiguanidine,Glucophage,Metformin HCl,Metformin Hydrochloride,HCl, Metformin,Hydrochloride, Metformin
D009303 Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX. Cancer of Nasopharynx,Nasopharyngeal Cancer,Cancer of the Nasopharynx,Nasopharynx Cancer,Nasopharynx Neoplasms,Neoplasms, Nasopharyngeal,Cancer, Nasopharyngeal,Cancer, Nasopharynx,Cancers, Nasopharyngeal,Cancers, Nasopharynx,Nasopharyngeal Cancers,Nasopharyngeal Neoplasm,Nasopharynx Cancers,Nasopharynx Neoplasm,Neoplasm, Nasopharyngeal,Neoplasm, Nasopharynx,Neoplasms, Nasopharynx
D011836 Radiation Tolerance The ability of some cells or tissues to survive lethal doses of IONIZING RADIATION. Tolerance depends on the species, cell type, and physical and chemical variables, including RADIATION-PROTECTIVE AGENTS and RADIATION-SENSITIZING AGENTS. Radiation Sensitivity,Radiosensitivity,Sensitivity, Radiation,Tolerance, Radiation,Radiation Sensitivities,Radiation Tolerances,Radiosensitivities,Sensitivities, Radiation,Tolerances, Radiation
D011838 Radiation-Sensitizing Agents Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells. Radiation Sensitizer,Radiosensitizing Agent,Radiosensitizing Agents,Agents, Radiation-Sensitizing,Radiation Sensitizers,Radiation Sensitizing Agents,Radiation-Sensitizing Drugs,Radiation-Sensitizing Effect,Radiation-Sensitizing Effects,Radiosensitizing Drugs,Radiosensitizing Effect,Radiosensitizing Effects,Agent, Radiosensitizing,Agents, Radiation Sensitizing,Agents, Radiosensitizing,Drugs, Radiation-Sensitizing,Drugs, Radiosensitizing,Effect, Radiation-Sensitizing,Effect, Radiosensitizing,Effects, Radiation-Sensitizing,Effects, Radiosensitizing,Radiation Sensitizing Drugs,Radiation Sensitizing Effect,Radiation Sensitizing Effects,Sensitizer, Radiation,Sensitizers, Radiation,Sensitizing Agents, Radiation
D002277 Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for "cancer." Carcinoma, Anaplastic,Carcinoma, Spindle-Cell,Carcinoma, Undifferentiated,Carcinomatosis,Epithelial Neoplasms, Malignant,Epithelioma,Epithelial Tumors, Malignant,Malignant Epithelial Neoplasms,Neoplasms, Malignant Epithelial,Anaplastic Carcinoma,Anaplastic Carcinomas,Carcinoma, Spindle Cell,Carcinomas,Carcinomatoses,Epithelial Neoplasm, Malignant,Epithelial Tumor, Malignant,Epitheliomas,Malignant Epithelial Neoplasm,Malignant Epithelial Tumor,Malignant Epithelial Tumors,Neoplasm, Malignant Epithelial,Spindle-Cell Carcinoma,Spindle-Cell Carcinomas,Tumor, Malignant Epithelial,Undifferentiated Carcinoma,Undifferentiated Carcinomas
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004260 DNA Repair The removal of DNA LESIONS and/or restoration of intact DNA strands without BASE PAIR MISMATCHES, intrastrand or interstrand crosslinks, or discontinuities in the DNA sugar-phosphate backbones. DNA Damage Response
D006657 Histones Small chromosomal proteins (approx 12-20 kD) possessing an open, unfolded structure and attached to the DNA in cell nuclei by ionic linkages. Classification into the various types (designated histone I, histone II, etc.) is based on the relative amounts of arginine and lysine in each. Histone,Histone H1,Histone H1(s),Histone H2a,Histone H2b,Histone H3,Histone H3.3,Histone H4,Histone H5,Histone H7
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077274 Nasopharyngeal Carcinoma A carcinoma that originates in the EPITHELIUM of the NASOPHARYNX and includes four subtypes: keratinizing squamous cell, non-keratinizing, basaloid squamous cell, and PAPILLARY ADENOCARCINOMA. It is most prevalent in Southeast Asian populations and is associated with EPSTEIN-BARR VIRUS INFECTIONS. Somatic mutations associated with this cancer have been identified in NPCR, BAP1, UBAP1, ERBB2, ERBB3, MLL2, PIK3CA, KRAS, NRAS, and ARID1A genes. Carcinoma, Nasopharyngeal,Carcinomas, Nasopharyngeal,Nasopharyngeal Carcinomas

Related Publications

Haiwen Li, and Xinggui Chen, and Ying Yu, and Zhennan Wang, and Yufang Zuo, and Shuhui Li, and Donghong Yang, and Shengwen Hu, and Mei Xiang, and Zumin Xu, and Zhonghua Yu
July 2016, Thoracic cancer,
Haiwen Li, and Xinggui Chen, and Ying Yu, and Zhennan Wang, and Yufang Zuo, and Shuhui Li, and Donghong Yang, and Shengwen Hu, and Mei Xiang, and Zumin Xu, and Zhonghua Yu
June 2021, Free radical biology & medicine,
Haiwen Li, and Xinggui Chen, and Ying Yu, and Zhennan Wang, and Yufang Zuo, and Shuhui Li, and Donghong Yang, and Shengwen Hu, and Mei Xiang, and Zumin Xu, and Zhonghua Yu
February 2024, Anti-cancer drugs,
Haiwen Li, and Xinggui Chen, and Ying Yu, and Zhennan Wang, and Yufang Zuo, and Shuhui Li, and Donghong Yang, and Shengwen Hu, and Mei Xiang, and Zumin Xu, and Zhonghua Yu
April 2017, Oncology reports,
Haiwen Li, and Xinggui Chen, and Ying Yu, and Zhennan Wang, and Yufang Zuo, and Shuhui Li, and Donghong Yang, and Shengwen Hu, and Mei Xiang, and Zumin Xu, and Zhonghua Yu
November 2010, Cancer research,
Haiwen Li, and Xinggui Chen, and Ying Yu, and Zhennan Wang, and Yufang Zuo, and Shuhui Li, and Donghong Yang, and Shengwen Hu, and Mei Xiang, and Zumin Xu, and Zhonghua Yu
January 2012, Asian Pacific journal of cancer prevention : APJCP,
Haiwen Li, and Xinggui Chen, and Ying Yu, and Zhennan Wang, and Yufang Zuo, and Shuhui Li, and Donghong Yang, and Shengwen Hu, and Mei Xiang, and Zumin Xu, and Zhonghua Yu
September 2020, Annals of palliative medicine,
Haiwen Li, and Xinggui Chen, and Ying Yu, and Zhennan Wang, and Yufang Zuo, and Shuhui Li, and Donghong Yang, and Shengwen Hu, and Mei Xiang, and Zumin Xu, and Zhonghua Yu
November 2015, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Haiwen Li, and Xinggui Chen, and Ying Yu, and Zhennan Wang, and Yufang Zuo, and Shuhui Li, and Donghong Yang, and Shengwen Hu, and Mei Xiang, and Zumin Xu, and Zhonghua Yu
February 2007, International journal of oncology,
Haiwen Li, and Xinggui Chen, and Ying Yu, and Zhennan Wang, and Yufang Zuo, and Shuhui Li, and Donghong Yang, and Shengwen Hu, and Mei Xiang, and Zumin Xu, and Zhonghua Yu
January 2019, OncoTargets and therapy,
Copied contents to your clipboard!